Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.36
-$0.01-0.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | 18.60K | 55.90K | 92.80K | 129.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | 18.60K | 55.90K | 92.80K | 129.20K |
| Cost of Revenue | 1.35M | 109.30K | -5.31M | -4.63M | -2.98M |
| Gross Profit | -351.40K | -90.70K | 5.37M | 4.72M | 3.11M |
| SG&A Expenses | 7.44M | 6.13M | 5.95M | 5.69M | 5.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.42M | 11.87M | 12.33M | 12.76M | 14.59M |
| Operating Income | -13.42M | -11.85M | -12.28M | -12.66M | -14.46M |
| Income Before Tax | -9.27M | -7.44M | -7.99M | -8.43M | -14.46M |
| Income Tax Expenses | 158.40K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.43 | -7.44 | -7.99 | -8.43 | -14.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.43M | -7.44M | -7.99M | -8.43M | -14.46M |
| EBIT | -13.42M | -11.85M | -12.28M | -12.66M | -14.46M |
| EBITDA | -13.41M | -11.84M | -12.26M | -12.65M | -14.45M |
| EPS Basic | -9.82 | -10.72 | -24.14 | -42.21 | -103.25 |
| Normalized Basic EPS | -6.09 | -6.70 | -15.09 | -26.38 | -64.53 |
| EPS Diluted | -9.90 | -10.80 | -24.22 | -42.29 | -103.25 |
| Normalized Diluted EPS | -6.11 | -6.72 | -15.11 | -26.40 | -64.53 |
| Average Basic Shares Outstanding | 4.17M | 2.62M | 1.90M | 1.44M | 955.00K |
| Average Diluted Shares Outstanding | 4.20M | 2.66M | 1.93M | 1.47M | 955.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |